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http://dx.doi.org/10.1016/j.jacl.2014.11BACKGROUND: Discordance between measures of atherogenic lipoprotein particle number (apoli-
poprotein B [ApoB] and low-density lipoprotein [LDL] particle number by nuclear magnetic resonance
spectroscopy [LDL-PNMR]) is not well understood. Appropriate treatment considerations in such cases
are unclear.
OBJECTIVES: To assess discordance between apoB determined by immunoassay and LDL-PNMR in
routine clinical practice, and to characterize biomarker profiles and other clinical characteristics of pa-
tients identified as discordant.
METHODS: Two retrospective cohorts were evaluated. First, 412,013 patients with laboratory
testing performed by Health Diagnostic Laboratory, Inc., as part of routine care; and second, 1411
consecutive patients presenting for risk assessment/reduction at 6 US outpatient clinics. Discordance
was quantified as a percentile difference (LDL-PNMR percentile 2 apoB percentile) and attainment
of percentile cutpoints (LDL-PNMR $ 1073 nmol/L or apoB $ 69 mg/dL). A wide range of cardiovas-
cular risk factors were compared.
RESULTS: ApoB and LDL-PNMR values were highly correlated (R
2 5 0.79), although substantial
discordance was observed. Similar numbers of patients were identified as at-risk by LDL-PNMR
when apoB levels were , 69 mg/dL (5%-6%) and by apoB values when LDL-PNMR was
, 1073 nmol/L (6%-7%). Discordance (LDL-PNMR . apoB) was associated with insulin resistance,
smaller LDL particle size, increased systemic inflammation, and low circulating levels of ‘‘traditional’’
lipids, whereas discordance (apoB . LDL-PNMR) was associated with larger LDL particle size, and
elevated levels of lipoprotein(a) and lipoprotein-associated phospholipase A2 (Lp-PLA2).nostic Laboratory, Inc. 737 N 5th E-mail address: svarvel@hdlabinc.com
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widespread than currently recognized and may be associated with insulin resistance.
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creativecommons.org/licenses/by-nc-nd/3.0/).Introduction coronary calcium or carotid intima-media thickness thanCalculated or measured low-density lipoprotein choles-
terol (LDL-C) concentration has long been the major goal
of lipid-modulating therapies.1 However, many individuals
experience cardiovascular disease (CVD)-related events or
progression of atherosclerosis despite having optimal
LDL-C; in fact, half of all patients hospitalized with cor-
onary artery disease have LDL-C levels at or below previ-
ously recommended targets.2 This residual or ‘‘hidden’’
risk—not identifiable by measuring LDL-C—contributes
substantially to CVD-related morbidity and mortality and
underscores the need for identification of prognostic lipo-
protein parameters that transcend cholesterol content.
Recent recommendations promulgated in the American
College of Cardiology/American Heart Association Treat-
ment of Blood Cholesterol guidelines noted the lack of
high-level evidence supporting continued treatment to spe-
cific LDL-C target values.3 In 2006, a group of 30 experts
from 10 different countries published a consensus paper4
citing multiple large studies, including the Apoprotein-
related Mortality Risk Study5 and the INTERHEART
Study,6 noting that the potential for future CVD events
is better reflected by measures of circulating atherogenic
particle concentration—specifically, apoB—than by
LDL-C.
ApoB, of which there is one copy per lipoprotein
particle, is found on several potentially atherogenic lipo-
proteins, including LDL, very-low-density lipoprotein
(VLDL), intermediate-density lipoprotein (IDL), and lip-
oprotein(a) (Lp(a)); however, because of the long plasma
residence time of LDL compared with that of VLDL and
IDL, 90% or more of all apoB is associated with LDL.
ApoB measurement therefore provides a reasonable
approximation of circulating LDL particle concentration
(LDL-P).7 Most apoB assay methods are immunoassays in
which specific antibodies are used to precipitate apoB in the
liquid phase, with the immunocomplexes then quantitated
using turbidimetric or nephelometric approaches. Among
methods available for LDL-P measurement, that using nu-
clear magnetic resonance spectroscopy (LDL-PNMR) is by
far the best validated, and the only assay cited by organiza-
tional position statements. On the basis of clinical trial data,
these statements have advocated the use of either (or both)
apoB and LDL-PNMR.
8–14 The latter biomarker is sup-
ported by multiple large prospective cohort studies that
have monitored clinical outcomes, including the Women’s
Health Study,15–17 the Framingham Offspring Heart
Study,18 and the Multi-Ethnic Study of Atherosclerosis.19
LDL-P also appears to be the better indicator of subclini-
cal CVD because it associates more strongly withdoes LDL-C.20,21
The superiority of apoB and LDL-P for cardiovascular
(CV) risk assessment is most evident when LDL-C and
LDL-P/apoB are discordant—a phenomenon that is espe-
cially prevalent among individuals with components of the
metabolic syndrome or evidence of insulin resistance22,23
and in those taking medications, such as statins, that reduce
LDL-C to a greater extent than LDL-P.10,24 In such settings,
LDL-C, compared with apoB or LDL-P, has been shown to
significantly mischaracterize CVD risk.25,26 Because those
with discordantly high LDL-P or apoB tend to have small,
cholesterol-depleted LDL and other evidence of insulin
resistance, consideration of particle number helps identify
high-risk individuals who would have otherwise been over-
looked because of their ‘‘optimal’’ LDL-C levels, an esti-
mated 34% of the population.27
Importantly, the relationship between LDL-P or apoB
and CV events is maintained on treatment. Although statins
can effectively lower LDL-C in individuals with a wide
spectrum of CV risk, they reduce CV event incidence by
only 25%-30%.28 This substantial residual risk may be
partly attributed to the fact that statin treatment unequally
affects LDL-C and LDL-P or apoB levels, reducing
LDL-C to the 21st percentile of the population but reducing
apoB and LDL-PNMR to only the 55th and 51st percentiles,
respectively.26 Accordingly, many clinical trials of lipid-
lowering agents have demonstrated that future CV events
are strongly predicted by on-treatment apoB and LDL-
PNMR, but not LDL-C; apoB and LDL-PNMR thus provide
a more reliable assessment of treatment efficacy.29–33 The
use of LDL-PNMR to guide patient care has been shown
to result in lower health care costs, fewer CV events, and
greater improvements in lipoprotein profile than the use
of LDL-C alone.34
Although most studies evaluating both apoB and LDL-
PNMR have demonstrated that these measures are similarly
associated with clinical outcomes, a recent review of 25
studies including 85 clinical outcomes concluded that out-
comes were significantly associated with both biomarkers
in 58.8% of comparisons, with neither in 20%, and with
only 1 biomarker in 21.1%.35 In a more in-depth critique
of this review, Master and Rader suggest that although
apoB and LDL-PNMR were comparable at the level of
bare statistical association with CV events, LDL-PNMR
was more strongly related to outcomes than was apoB in
the majority of studies.36 The present study was conducted
to determine the extent of discordance between apoB and
LDL-PNMR in a large patient cohort, to characterize the
biomarker profiles of patients with discordant apoB and
LDL-PNMR, and to evaluate the potential role of treatment
Varvel et al ApoB/LDL-P discordance 249effects and insulin resistance in a subset of patients for
whom additional data were available.Figure 1 Relationship between low-density lipoprotein particle
concentration (LDL-P; nmol/L) and apolipoprotein B (apoB; mg/
dL) values in 412,013 consecutive patients. Lightly shaded areas
indicate the first (discordant LDL-P. apoB, bottom right) and fifth
(discordant apoB.LDL-P, top left) quintiles of discordance scores.Methods
Subjects
Discordance between LDL-PNMR and apoB was investi-
gated in 2 different retrospective cohorts. The first con-
sisted of deidentified laboratory data from 412,013
consecutive, unique patients who had laboratory testing
performed by Health Diagnostic Laboratory (HDL, Inc.)
as part of routine clinical care. Only laboratory data, age,
and gender were available for these patients. The second
cohort was from a retrospective study of 1411 consecutive
patients presenting for risk assessment and risk reduction at
6 outpatient clinics across the United States. Family and
medical history, current medications, vital signs, and demo-
graphic information were collected from chart review and
matched to laboratory biomarker data, which was then de-
identified. The study protocol was approved and waivers of
informed consent were granted by the Copernicus Group
Institutional Review Board (Durham, NC).
Laboratory measurements
Blood samples were drawn after an overnight fast and
shipped with cold packs to HDL, Inc. for biomarker
testing. Samples were prepared at each clinical site accord-
ing to standardized instructions appropriate for specimen
type (BD Vacutainer SST ‘‘Tiger Top’’ tubes were used for
all tests except Vacuette Z Serum Sep. Clot Activator
‘‘Bumble Bee Top’’ tubes used for NMR analysis and BD
Vacutainer K2 Whole Blood ‘‘Lavender Top’’ tubes used
for HbA1c), received at HDL, Inc. within 24 hours, and
tested immediately. ApoB was analyzed using an immuno-
turbidimetric assay from Roche Diagnostics (Indianapolis,
IN) on a Roche/Hitachi P-Modular system. LDL-C and
high-density lipoprotein cholesterol (HDL-C) were
measured using direct enzymatic assays (Beckman-Coulter
Biomedical Ltd., Co. Clare, Ireland). LDL-PNMR, high-
density lipoprotein particle number (HDL-P), and other
lipoprotein parameters were measured at LipoScience (Ra-
leigh, NC) as described previously.16 Triglyceride assay
was performed using standard automated enzymatic
methods (Roche Diagnostics), high-sensitivity C-reactive
protein (hs-CRP) by immunoturbidimetric assay (Roche
Diagnostics), and lipoprotein-associated phospholipase A2
(Lp-PLA2) by enzyme-linked immunosorbent assay
(PLAC Test ELISA kit; diaDexus, Inc., San Francisco,
CA). Metabolic biomarkers were measured as follows: fast-
ing glucose by an ultraviolet method (Roche Diagnostics)
on a Beckman AU5800 analyzer; HbA1c by high-
performance liquid chromatography (VARIANT II TURBO
HbA1c Kit; Bio-Rad, Hercules, CA); leptin and proinsulin
by enzyme-linked immunosorbent assay (Mercodia, Inc.,Winston-Salem, NC) on a DSX analyzer; adiponectin by la-
tex turbidimetric immunoassay (MedtestDx, Canton, MI)
on a Beckman AU5800 analyzer; free fatty acids by an
enzymatic colorimetric method (Wako Chemicals USA,
Inc., Richmond, VA) on a Beckman AU5800 analyzer;
ferritin by a sandwich principle method (latex agglutina-
tion; Roche Diagnostics); and insulin and C-peptide by
electrochemiluminescence immunoassay (Roche Diagnos-
tics) on a Roche E module analyzer. The leptin-to-adipo-
nectin (leptin:adiponectin) ratio was calculated as leptin
(ng/mL)/adiponectin (mg/mL). The homeostatic model
assessment of insulin resistance (HOMA-IR), a surrogate
measure of insulin resistance, was calculated as: glucose
(mg/dL) ! insulin/405 (mU/mL).
Statistical analysis
Two methods were used to characterize discordance.
First, an ApoB/LDL-PNMR discordance score (DS) was
calculated for each patient. LDL-PNMR and apoB values
were converted into percentiles and subtracted
(DS 5 apoB percentile 2 LDL-PNMR percentile),
providing a normalized measure of discordance. Differ-
ences between DS quintiles were assessed with one-way
analysis of variance (ANOVA) or Pearson chi-square tests,
and Spearman rank correlation coefficients were calculated
to evaluate the linear relationship between DS and each
dependent measure. All dependent measures with non-
normal distributions were log-transformed. Significant
ANOVA results were followed with Bonferroni-adjusted
Dunnett tests comparing the first and fifth quintiles (most
discordant) with the third (most concordant).
Second, discordancewas defined as agreement (Y/N) with
reference to population cutpoints established within the large
cohort. Specifically, the 20th percentile of apoB (69 mg/dL)
and LDL-PNMR (1073 nmol/L) were used in this analysis
to define potential risk thresholds. All subjects were then
Figure 2 Distribution of the apolipoprotein B (apoB)/low-den-
sity lipoprotein particle concentration (LDL-P) discordance score
(apoB percentile 2 LDL-P percentile), N 5 412,013. Dashed
lines indicate quintile boundaries.
250 Journal of Clinical Lipidology, Vol 9, No 2, April 2015classified in one of four categories: both low, discordant
(LDL-PNMR . apoB), discordant (apoB . LDL-PNMR),
or both high. Differences in biomarkers and other parameters
between clinical risk categories were assessed with 1-way
ANOVA or Pearson chi-square tests as appropriate. Signifi-
cant results were followed with Bonferroni-adjusted DunnettTable 1 Patient characteristics (6SD) by quintiles of the ApoB/LDL
N 5 412,013
Patient characteristics
ApoB/LDL-P discordance score quintiles
First (LDL-P . ApoB) Second Thir
Demographics
Gender (% F) 47.8* 47.9 49.
Age 58.3 (13.9)* 57.3 (14.3) 56.
Lipids
TCHOL (mg/dL) 161 (29)* 175 (39) 19
LDL-C (mg/dL) 86.1 (20.5)* 96.2 (29.8) 109.
HDL-C (mg/dL) 46.8 (11.9)* 49.3 (12.6) 52.
TG (mg/dL) 132 (75)* 139 (8) 15
Lipoproteins/apolipoproteins
ApoB (mg/dL) 80.1 (15.6)* 88.0 (24.0) 99.
LDL-P (nmol/L) 1596 (366)* 1603 (555) 169
LDL size (nm) 20.5 (0.5)* 20.6 (0.5) 20.
ApoA-I (mg/dL) 140 (28)* 142 (28) 14
HDL-P (mmol/L) 33.7 (7.4)* 34.0 (7.1) 34.
HDL size (nm) 8.6 (0.4)* 8.7 (0.4) 8.
Lp(a) mass (mg/dL) 31.4 (37.5)* 32.3 (38.2) 33.
Inflammation/metabolic
hs-CRP (mg/L) 4.8 (10.2)* 4.3 (8.1) 4.
Lp-PLA2 (ng/mL) 136 (41)* 142 (41) 14
Insulin (mU/mL) 17.0 (21.3)* 16.2 (19.8) 15.
ApoA-I, apolipoprotein A-I; ApoB, apolipoprotein B; F, female; HDL-C, low-
concentration; hs-CRP, high-sensitivity C-reactive protein; LDL-C, low-density
tration; Lp(a), lipoprotein(a); Lp-PLA2, lipoprotein-associated phospholipase A
*Indicates significant differences in the first and fifth quintiles compared
†The linear trends are characterized by Spearman’s rho; significance is indtests comparing groups against the ‘‘both low’’ group. The
smaller cohort was evaluated in the same manner. Patients
currently taking exogenous insulin (n5 189) were excluded
from analysis of insulin levels (and HOMA-IR) to avoid
confounding effects.Results and discussion
Characterization of ApoB/LDL-PNMR discordance
in a large clinical dataset
As expected, LDL-PNMR and apoB were strongly corre-
lated (R25 0.79; Fig. 1). The median values for LDL-PNMR
and apoB in this large cohort were 1459 nmol/L and
88 mg/dL, respectively—comparable to the 50th percen-
tiles reported in the Framingham Offspring Study.2 Despite
this strong correlation, a high degree of discordance was
observed. As shown in Figure 2, the discordance scores
(apoB percentile 2 LDL-PNMR percentile) were normally
distributed (skewness 5 0.2, kurtosis 5 1.4), with the first
and fifth quintiles trailing off either side of the mean and
showing at least a 10-percentile-unit difference. The light
shading in Figure 1 illustrates the actual values of LDL-
PNMR and apoB for the first quintile (discordant-P discordance score (apoB percentile 2 LDL-P percentile),
Linear trend
(Spearman’s rho)d Fourth
Fifth
(ApoB . LDL-P)
3 50.8 55.9* —
7 (14.7) 56.6 (14.9) 56.8 (14.9)* 20.04†
4 (57) 190 (41) 195 (36)* 0.30†
4 (45.5) 106.2 (34.6) 105.9 (26.9)* 0.23†
2 (13.7) 55.0 (15.2) 60.4 (18.2)* 0.31†
2 (101) 138 (87) 143 (146)* 20.02†
1 (37.9) 94.7 (26.4) 94.9 (18.1)* 0.22†
3 (778) 1456 (484) 1276 (309)* 20.24†
7 (0.6) 20.9 (0.6) 21.0 (0.6)* 0.32†
6 (29) 150 (30) 158 (33)* 0.21†
0 (7.1) 34.9 (7.1) 36.0 (7.3)* 0.11†
8 (0.5) 8.9 (0.5) 9.0 (0.6)* 0.29†
7 (39.7) 35.1 (40.6) 37.2 (42.9)* 0.05†
2 (8.2) 3.7 (6.94) 3.6 (8.2)* 20.08†
7 (42) 154 (42) 162 (43)* 0.23†
5 (19.2) 14.5 (17.7) 13 (16.8)* 20.14†
density lipoprotein cholesterol; HDL-P, high-density lipoprotein particle
lipoprotein cholesterol; LDL-P, low-density lipoprotein particle concen-
2; SD, standard deviation; TCHOL, total cholesterol; TG, triglycerides.
with the third (P , .0001).
icated by P , .0001.
Table 2 Mean biomarker values (6SD) by discordance risk category (ApoB $ 69 mg/dL and/or LDL-P $ 1073 nmol/L), N 5 412,013
Patient characteristics
ApoB/LDL-P discordance risk categories ANOVA
(P value)
Both low
n 5 61,033 (15%)
High ApoB
n 5 21,415 (5%)
High LDL-P
n 5 25,023 (6%)
Both high
n 5 304,542 (74%)
Demographics
Gender (% F) 48.2 58.0* 44.9* 50.7* —
Age 60.3 (16.3) 58.1 (15.8)* 60.6 (14)* 56.2 (14)* ,.0001
Lipids
TCHOL (mg/dL) 137 (25) 174 (32)* 138 (20)* 197 (39)* ,.0001
LDL-C (mg/dL) 59.3 (13.1) 82.7 (15.1)* 67.8 (10.4)* 113 (30)* ,.0001
HDL-C (mg/dL) 54.7 (17.7) 63.0 (20.0)* 46.9 (12.9)* 52.1 (14.1)* ,.0001
TG (mg/dL) 100 (63) 135 (195)* 108 (47)* 152 (98)* ,.0001
Lipoproteins/apolipoproteins
ApoB (mg/dL) 56.9 (8.4) 77.6 (8.4)* 63.9 (4.8)* 101 (23)* ,.0001
LDL-P (nmol/L) 818 (177) 951 (110)* 1220 (128)* 1732 (467)* ,.0001
LDL size (nm) 20.9 (0.6) 21.1 (0.6)* 20.6 (0.5)* 20.7 (0.6)* ,.0001
ApoA-I (mg/dL) 150 (33) 162 (35)* 139 (28)* 146 (29)* ,.0001
HDL-P (mmol/L) 35.1 (7.1) 36.7 (7.3)* 34.2 (7.12)* 34.3 (7.2)* ,.0001
HDL size (nm) 9.12 (0.56) 9.27 (0.56)* 8.73 (0.40)* 8.7 (0.43)* ,.0001
Lp(a) mass (mg/dL) 28.3 (33.4) 35.9 (41.8)* 29.9 (35.7)* 35.2 (41.1)* ,.0001
Inflammation/metabolic
hs-CRP (mg/L) 3.2 (7.8) 3.4 (8.1)* 4.0 (9.1)* 4.4 (8.5)* ,.0001
Lp-PLA2 (ng/mL) 149 (44) 161 (43.2)* 137 (41.1)* 148 (42.3)* ,.0001
Insulin (mU/mL) 14.2 (19.2) 12.4 (17.5)* 16.3 (20.2)* 15.6 (19.1)* ,.0001
ANOVA, analysis of variance; ApoA-I, apolipoprotein A-I; ApoB, apolipoprotein B; F, female; HDL-C, low-density lipoprotein cholesterol; HDL-P, high-
density lipoprotein particle concentration; hs-CRP, high-sensitivity C-reactive protein; LDL-C, low-density lipoprotein cholesterol; LDL-P, low-density
lipoprotein particle concentration; Lp(a), lipoprotein(a); Lp-PLA2, lipoprotein-associated phospholipase A2; SD, standard deviation; TCHOL, total choles-
terol; TG, triglycerides.
*Denotes significant differences compared with the ‘‘both low’’ group (P , .0001).
Varvel et al ApoB/LDL-P discordance 251LDL-PNMR . apoB, bottom right) and fifth quintile
(discordant apoB . LDL-PNMR, top left).
Demographic and biomarker data are presented in
Table 1 by ApoB/LDL-PNMR discordance score quintile
(mean, standard deviation), with the first quintile represent-
ing the 20% most discordant (LDL-PNMR . apoB) and the
fifth quintile representing the 20% most discordant
(apoB . LDL-PNMR). This method of presenting normal-
ized discordance scores was chosen to investigate correlates
of discordance independent of their absolute values. In
comparing the first quintile (discordant, LDL-
PNMR . apoB) with the third (most concordant) quintile,
several trends are evident. Specifically, these patients
tended to have lower lipid levels (total cholesterol, LDL-
C, HDL-C, triglycerides [TG]), lower apoB and apoA-I
values, smaller LDL-PNMR and HDL-P size, and lower
Lp(a) mass (Table 1). Circulating levels of insulin and
hs-CRP were higher in this group, though Lp-PLA2 was
lower. In contrast, the fifth quintile (discordant,
apoB . LDL-PNMR) was characterized by lower but larger
LDL-PNMR, higher HDL-C, larger and increased HDL-P,
higher apoA-I, and lower hs-CRP and insulin, but higher
Lp(a) mass and Lp-PLA2. Analysis of these biomarkers
as continuous variables revealed significant linear associa-
tions with ApoB/LDL-PNMR discordance score, as shown
in Table 1. The strongest linear trends were observed for
LDL size (r 5 0.32, P , .0001), HDL-C (r 5 0.31,P , .0001), total cholesterol (r 5 0.30, P , .0001), and
HDL size (r 5 0.29, P , .0001).
The reason for this relatively high incidence of discor-
dance between apoB assessment and NMR-determined
LDL-P is not clear. Conceptually, because apoB is also a
constituent of non-LDL atherogenic lipoproteins such as
VLDL, IDL, and Lp(a), it could be hypothesized that
discordance could result when these other apoB-containing
particles constitute a higher than typical percentage of total
apoB. In fact, we do report here an increase in Lp(a) mass
in those discordant apoB . LDL-PNMR patients. However,
because NMR does not typically differentiate Lp(a) or even
IDL particles from LDL particles, this would require a
much higher number of VLDL particles (and presumably
of TG) than is ever seen, except in very rare cases resulting
from genetic disorders. Our present data are not consistent
with this explanation, because TG values were actually
lower in the discordant group with higher than expected
apoB compared with the third (most concordant) quintile,
and the linear association between TG and discordance
was close to zero.
The observations that the discordance scores are so
normally distributed and linearly associated with several
relevant biomarkers suggests an alternative hypothesis.
Specifically, reduced LDL size, decreased HDL size and
particle number, increased systemic inflammation, and
increased insulin levels are all consistent with insulin
Table 3 Patient characteristics by discordance risk category, N 5 1411
Patient characteristics
ApoB/LDL-P discordance risk categories
ANOVA or Pearson
(P value)
Both low
n 5 383 (27%)
High ApoB
n 5 103 (7%)
High LDL-P
n 5 89 (6%)
Both high
n 5 836 (59%)
Demographic
Age (y) 54.6 (14.2) 55.5 (13.8) 51.6 (15.1) 51.9 (14.7)* ,.01
Gender (% F) 206 (54) 65 (63) 51 (57) 515 (62)* .08
Caucasian‡ 158 (68%) 42 (67%) 32 (52%) 373 (68%) .23
Clinical
BMI (kg/m2) 30.5 (6.6) 31.6 (6.2) 29.7 (7.1) 30.6 (7.0) .27
Systolic BP (mmHg) 122 (16) 121 (15) 121 (16) 123 (17) .37
Diastolic BP (mmHg) 74.8 (10.0) 75.4 (10.6) 76.3 (10.1) 76.8 (10.6)* ,.05
Currently smoking 28 (7.3%) 5 (4.9%) 7 (7.9%) 56 (6.7%) .73
LDL-C , 100 mg/dL 382 (99%) 99 (96%)* 88 (99%) 367 (44%)* ,.0001
Lp(a) mass . 30 mg/dL 137 (36%) 45 (44%) 35(40%) 370 (44%)* ,.0001
Medical history
T2DM 140 (37%) 27 (26%) 39 (44%)† 211 (25%)* ,.0001
Hypertension 211 (55%) 38 (37%)* 51 (57%)† 375 (45%)* ,.0001
CAD 108 (28%) 18 (17%) 16 (18%) 106 (13%)* ,.0001
Current medications
Any antidiabetic 222 (58%) 39 (38%)* 50 (56%)† 341 (41%)* ,.0001
Insulin 59 (15%) 11 (11%) 14 (16%) 105 (13%) .41
Metformin 179 (47%) 32 (31%)* 35 (39%) 252 (30%)* ,.0001
Thiazolidinediones 41 (11%) 7 (7%) 3 (3%) 29 (3%)* ,.0001
Secretagogues 13 (3%) 4 (4%) 2 (2%) 26 (3%) .92
Incretin mimetics 92 (24%) 17 (17%) 23 (26%) 101 (12%)* ,.0001
Any lipid-lowering 318 (83%) 70 (68%)* 78 (88%)† 582 (70%)* ,.0001
Statins 284 (74%) 53 (51%)* 70 (79%)† 399 (48%)* ,.0001
Fibrates 20 (5%) 5 (5%) 8 (9%) 36 (4%) .27
Niacin 87 (23%) 20 (19%) 15 (17%) 93 (11%)* ,.0001
Ezetimibe (Zetia) 63 (16%) 10 (10%) 15 (17%) 82 (10%)* ,.01
Bile acid sequestrant 19 (5%) 3 (3%) 8 (9%) 62 (7%) .13
Any antihypertensive 220 (57%) 39 (38%)* 55 (62%)† 400 (48%)* ,.0001
Any anti-inflammatory 208 (54%) 45 (44%) 47 (53%) 357 (43%)* ,.01
ANOVA, analysis of variance; ApoB, apolipoprotein B; F, female; BP, blood pressure; BMI, body mass index; CAD, coronary artery disease; LDL-C, low-
density lipoprotein cholesterol; LDL-P, low-density lipoprotein particle concentration; Lp(a), lipoprotein(a); T2DM, type 2 diabetes mellitus.
Continuous and categorical variables are reported as ‘‘mean (standard deviation)’’ and ‘‘number of patients (% of discordance subgroup),’’ respectively.
*Denotes significant differences compared with the ‘‘both low’’ group (P , .01).
†Denotes significant differences between the two discordant groups (P , .01).
‡n 5 911.
252 Journal of Clinical Lipidology, Vol 9, No 2, April 2015resistance or the metabolic syndrome. The effects of
insulin resistance on lipoprotein profiles have been well
characterized,23,37 associated with production of smaller,
denser, cholesterol-depleted—and potentially more
atherogenic—LDL particles. It is possible, and to our
knowledge not yet directly investigated, that the effi-
ciency of current immunoassays for apoB may vary
with respect to particle size or shape because of confor-
mational changes in the binding epitope of apoB as the
particle shrinks or distorts. It is also possible that an in-
flammatory milieu and/or metabolic disease can lead to
oxidative, thermotropic, or glycative epitope changes, re-
sulting in a false-negative apoB measurement.38,39 Such a
mechanism could explain why apoB appears to underes-
timate LDL particle number under conditions of insulin
resistance.Clinical relevance of apoB/LDL-P discordance
To evaluate the potential clinical significance of this
discordance (eg, determine how often it may affect a
treatment decision), the same cohort was recategorized
according to whether each patient had values above the
20th percentile of apoB (69 mg/dL) and/or LDL-PNMR
(1073 nmol/L). As shown in Table 2, 15% of patients had
‘‘low-risk’’ levels of both markers, whereas 74% had
‘‘high-risk’’ levels of both. Importantly, 6% of these pa-
tients had risk identified by LDL-PNMR even though their
apoB was considered normal, and 5% were identified to
be at risk on the basis of apoB but had normal LDL-
PNMR values. This relatively high incidence of discordance
is not dependent on the particular cutpoint used to define
risk; several other cutpoints were evaluated (eg, 50th
Table 4 Mean biomarker values (6SD) by discordance risk category, N 5 1411
Biomarker
ApoB/LDL-P discordance risk category
ANOVA
(P value)
Both low
n 5 383 (27%)
High ApoB
n 5 103 (7%)
High LDL-P
n 5 89 (6%)
Both high
n 5 836 (59%)
Lipids
TCHOL (mg/dL) 129 (26) 168 (24)* 135 (21)† 196 (43)* ,.0001
LDL-C (mg/dL) 55.2 (14.5) 78.3 (14.0)* 65.1 (11.6)*,† 111 (33)* ,.0001
HDL-C (mg/dL) 54.8 (18.2) 63.9 (19.8)* 47.6 (13.0)*,† 54.2 (15.5) ,.0001
TG (mg/dL) 88.5 (59.5) 124 (125)* 94.0 (43.7) 137 (107)* ,.0001
Lipoproteins
ApoB (mg/dL) 54.6 (9.8) 75.9 (6.7)* 62.8 (4.6)*,† 99.3 (23.9)* ,.0001
LDL-P (nmol/L) 764 (197) 903 (166)* 1222 (115)*,† 1684 (480)* ,.0001
LDL size (nm) 20.8 (0.6) 21.0 (0.6)* 20.5 (0.6)*,† 20.7 (0.6) ,.0001
ApoA-I (mg/dL) 148 (31) 157 (31)* 142 (28)† 148 (31) ,.01
HDL-P (mmol/L) 34.6 (6.5) 35.2 (6.4) 34.5 (6.7) 34.1 (7.2) .45
HDL size (nm) 9.16 (0.57) 9.33 (0.62)* 8.76 (0.44)*,† 8.80 (0.47)* ,.0001
Lp(a) mass (mg/dL) 33.1 (36.3) 41.2 (45.0) 36 (40.1) 42.3 (45.4) .10
Inflammation
hs-CRP (mg/L) 2.2 (3.3) 4.0 (11.0) 4.2 (6.8)* 3.6 (6.6)* ,.0001
Lp-PLA2 (ng/mL) 133 (39) 158 (40)* 127 (39)
† 144 (41)* ,.0001
Metabolic
Glucose (mg/dL) 99.8 (34.4) 97.3 (27.4) 102 (29) 102 (39) .64
HbA1c (%) 5.8 (1.1) 5.9 (1.2) 6.0 (1.2) 5.9 (1.4) .47
Insulin‡ (mU/mL) 12.4 (9.2) 12.2 (18.7) 15.5 (17.2)*,† 13.3 (13.3) ,.05
C-peptide (ng/mL) 2.97 (1.52) 2.63 (1.35) 3.4 (1.72)† 3.01 (1.69) ,.05
Proinsulin (pmol/L) 16.1 (23.8) 15.7 (20.0) 21.3 (22.6)*,† 18.3 (23.3) ,.01
FFA (mmol/L) 0.50 (0.24) 0.57 (0.27)* 0.52 (0.18) 0.57 (0.24)* ,.0001
Leptin (ng/mL) 34.4 (35.5) 32.2 (31.0) 38.8 (38.9) 34.7 (32.3) .29
Adiponectin (mg/mL) 17.7 (19.9) 16.6 (11.9) 12.4 (9.69)*,† 13.2 (10.1)* ,.0001
Leptin:adiponectin 3.36 (4.11) 2.94 (3.50) 4.96 (7.20)*,† 3.83 (4.24)* ,.001
HOMA-IR‡ 2.97 (2.65) 3.04 (6.22) 3.98 (5.66)† 3.41 (4.83) ,.05
ANOVA, analysis of variance; ApoA-I, apolipoprotein A-I; ApoB, apolipoprotein B; FFA, free fatty acids; LDL-P, low-density lipoprotein particle
concentration; HDL-C, low-density lipoprotein cholesterol; HDL-P, high-density lipoprotein particle concentration; HOMA-IR, homeostatic model
assessment of insulin resistance; hs-CRP, high-sensitivity C-reactive protein; LDL-C, low-density lipoprotein cholesterol; LDL-P, low-density lipoprotein
particle concentration; Lp-PLA2, lipoprotein-associated phospholipase A2; TCHOL, total cholesterol; TG, triglycerides.
*Denotes significant differences compared to the ‘‘both low’’ group (P , .05).
†Denotes significant differences between the 2 discordant groups (P , .05).
‡n 5 1222.
Varvel et al ApoB/LDL-P discordance 253percentiles) and similar proportions of discordant patients
were identified (data not shown). It is clear from Table 2
that both discordant groups are associated with significant
risk factors compared with the ‘‘both low’’ group. Particu-
larly, the discordant (LDL-PNMR . apoB) group has
smaller and more numerous LDL particles, higher inflam-
mation, and hyperinsulinemia, whereas the discordant
(apoB . LDL-PNMR) group has elevated levels of Lp(a)
mass.
Although intriguing, conclusions drawn from the obser-
vations described here are limited by a lack of patient
clinical information, such as medical history and current
treatment status. We therefore examined a separate cohort
of 1411 well-characterized, aggressively treated patients at
risk for cardiometabolic disease, with a high prevalence of
insulin resistance. Discordance scores were calculated as
described previously and were confirmed to have a distri-
bution almost identical to that presented in Figure 2 (seeSupplemental Fig. 1). Patient characteristics of this cohort
are presented in Table 3, separated by discordance risk
category using the same cutpoints of apoB $ 69 mg/dL
and LDL-PNMR $ 1073 nmol/L. The mean age was
53 6 15 years, 41% were male, 66% Caucasian, and
mean BMI was 30.6 6 6.8 kg/m2. A high proportion of
the sample had prior history of hypertension (48%), dia-
betes (30%), and coronary artery disease (18%), and was
currently taking lipid-lowering (74%), antihypertensive
(51%), and antidiabetic (46%) agents. A total of 27% of
these patients currently had ‘‘low-risk’’ levels of LDL-P
and apoB, whereas 59% had ‘‘high-risk’’ levels of both
measures. Importantly, 6% of these patients had risk iden-
tified by LDL-PNMR even though their apoB was consid-
ered normal—an identical proportion to that identified in
the larger cohort described previously. A similar number
of patients (7%) were identified to be at risk on the basis
of apoB but had normal LDL-PNMR values.
254 Journal of Clinical Lipidology, Vol 9, No 2, April 2015Laboratory biomarker values for these patients, also
separated by discordance risk category, are shown in
Table 4. Patterns of risk factors were similar to those
observed in the larger cohort. Specifically, the discordant
(LDL-PNMR . apoB) group had more numerous and
smaller LDL particles and evidence of insulin resistance,
compared with controls. It is worth noting that there was
no evidence in this group of differences in glycemic control
per se, nor of several other traditional markers of diabetes
risk such as BMI, triglycerides, or even free fatty
acids. However, significant differences noted for insulin,
HOMA-IR, adiponectin, leptin:adiponectin ratio, and even
proinsulin provide evidence of underlying insulin resistance
that corresponds to the insulin-resistant lipoprotein profile.
When compared with the discordant (apoB . LDL-PNMR)
patients, this group also shows significantly higher rates
of type 2 diabetes mellitus incidence and antidiabetic
treatment.
These observations illustrate the potential importance of
apoB/LDL-PNMR discordance in a real-world setting where
at-risk patients are being actively treated. It is very likely that
medication use affects the degree of discordance observed
here. For example, 79% of the LDL-PNMR . apoB group
were taking statins, in contrast to 51% of the
apoB . LDL-PNMR group. It has been shown previously
that statins are better at lowering LDL-C than they are at
lowering measures of LDL particles or apoB.26 Because
cholesterol-depleted particles tend to be smaller, the obser-
vation in the present study that discordance is linearly related
to particle size suggests that statin use may be a significant
factor in discordance between LDL-PNMR and apoB.
Regardless, 88% of the LDL-PNMR . apoB group were
currently on lipid-lowering medication, and 99% had
achieved LDL-C levels , 100 mg/dL; although measuring
LDL-PNMR in these individuals may have revealed high
numbers of atherogenic particles, an apoB test alone would
not have identified their presumably significant residual
risk. On the other side, the 7%of patients identified on the ba-
sis of apoBvalueswhen their LDL-PNMRwas, 1073 nmol/L
were more likely to have elevated plasma levels of Lp(a)
and Lp-PLA2. Interestingly, Lp-PLA2 has been reported to
show a stronger association for Lp(a) than for LDL parti-
cles.40 The majority of these patients were also currently
on lipid-lowering medication (68%) and 96% of them had
LDL-C levels , 100 mg/dL, suggesting residual
lipoprotein-related risk not identified by LDL-PNMR alone.Conclusion
The present data suggest that discordance between
apoB and LDL-PNMR is more widespread in routine clinical
practice than is currently recognized, and similar to
(perhaps even slightly higher than) that reported in the liter-
ature review by Cole et al.35 Discordance (LDL-
PNMR . apoB) was associated with insulin resistance,
smaller LDL particle size, increased systemicinflammation, and lower circulating levels of ‘‘traditional’’
lipids, whereas discordance (apoB. LDL-PNMR) was asso-
ciated with larger LDL particle size and elevated levels of
Lp(a) and Lp-PLA2. In both the large clinical dataset and
the smaller at-risk cohort, similar proportions of patients
were identified as at-risk by LDL-PNMR when their apoB
levels were , 69 mg/dL (5%-6%) and by apoB values
when their LDL-PNMR was ,1073 nmol/L (6%-7%). Until
this discordance can be correlated with clinical outcomes, it
is not possible to declare with certainty which particle
biomarker (if either) is the false positive or false negative.
Our analysis from a very large database suggests that both
can be helpful in the comprehensive assessment of cardio-
vascular risk related to increased atherogenic particle
burden, particularly when insulin resistance or Lp(a) abnor-
malities are present.Acknowledgments
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